PCM
HARP

Prelude Capital Management’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Prelude Capital Management’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-20
Closed -$3K – 2344
2019
Q3 		$3K Buy
+20
New +$2.81K ﹤0.01% 1608

Other funds holding HARP

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Prelude Capital Management's HARP Position: Q4 2019 in Review

Prelude Capital Management sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q4 2019, closing a stake of 20 shares — an estimated $3K sold.

Prelude Capital Management first reported a position in HARP in Q3 2019 and held it in 1 quarter. The position peaked at $3K in Q3 2019. 50 funds tracked by Wall St. Rank hold HARP as of Q4 2019.

  • Prelude Capital Management reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Prelude Capital Management sold 20 Harpoon Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $3K.
  • Prelude Capital Management first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • Prelude Capital Management's Harpoon Therapeutics, Inc. Common Stock position peaked at $3K in Q3 2019.
  • 50 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Prelude Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.